spacer
home > ebr > spring 2002 > preclinical and clinical evaluation of therapeutic vaccines - 21st-22nd january 2002, london
PUBLICATIONS
European Biopharmaceutical Review

Preclinical and Clinical Evaluation of Therapeutic Vaccines - 21st-22nd January 2002, London

Since as long ago as the 1890s, when William Coley used streptococcal cultures to treat patients with advanced sarcoma, it has been known that the immune system can be prompted to attack cancer cells. More recently, melanoma tumours in animals have been shown to regress when injected with modified autologous cancer cells primed to stimulate an immune response. And now, somewhat like the resurgence of interest surrounding recent therapeutic success with monoclonal antibodies, the concept of stimulating the immune system to recognise and destroy foreign or indeed tumour cells, so-called 'therapeutic vaccines', is, it seems, again in vogue.This kind of technology is distinct from normal vaccination in that the patient already has the disease or condition before the vaccine is given. For any number of reasons, the patient has not already responded to the disease-associated antigens - possibly because they are 'self'-antigens (on endogenous cells such as tumour cells), or they are hidden from the immune response by directly disrupting or affecting immune cell function (HIV).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott and Dr Keith Chidwick of Technomark Consulting Services Limited
spacer
Dr Helen Abbott
spacer
spacer
spacer
Dr Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Data custodianship of connected devices, environmental impact and adherence technologies highlighted at Pharmapack Europe 2020

Paris, 19th February 2020: Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as an excellent yardstick of the industry’s prospects for the year ahead. Encouragingly, the event played host a record 411 exhibiting companies, 5366 attendees and 325 delegates.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement